Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.42 |
| ▸ | FLT1 | P17948 | 13/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.40 |
| ▸ | KIT | P10721 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | FLT4 | P35916 | 2/20 | 0.35 |
| ▸ | CIT | O14578 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HLA-A | P04439 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | FRK | P42685 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681363 | 1.00 | KDR (0.42) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL1930677 | 0.86 | SHMT2 (0.42) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL1931665 | 0.85 | KDM4E (0.40) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL4679265 | 0.85 | KDM4E (0.40) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL4825401 | 0.79 | GRM4 (0.39) | KDM4EHSD17B10GRM4UTS2R | |
| SCHEMBL1383698 | 0.79 | GRM4 (0.39) | KDM4EHSD17B10GRM4UTS2R | |
| SCHEMBL1929839 | 0.77 | KDR (0.42) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL6612202 | 0.75 | FLT1 (0.63) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL6607319 | 0.71 | KDM4E (0.63) | KDRFLT1PDGFRBKITKDM4E | |
| SCHEMBL4820832 | 0.70 | KDR (0.55) | KDRFLT1PDGFRBKITKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399761-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | claimed |
| EP-1387836-B1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-1387836-A1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | Novartis AG (CH) | 2004-02-11 | — | — | EP | claimed |
| WO-2002090346-A1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2002-11-14 | — | — | WO | claimed |
| US-8034814-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | NOVARTIS AG | 2009-03-19 | — | — | US | disclosed |
| US-7399761-B2 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| EP-1387836-B1 | PHTHALAZINE DERIVATIVES WITH ANGIOGENESIS INHIBITING ACTIVITY | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076003-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDR 1/4885FLT1 2/4885PDGFRB 24/4885 |
| US-20110130399-A1 | Phthalazine Derivatives with Angiogenesis Inhibiting Activity | KDR, FLT1, FLT4 | KDR 1/4885FLT1 2/4885PDGFRB 16/4885 |
| US-20040180899-A1 | Phthalazine derivatives with angiogenesis inhibiting activity | VEGFA, NR5A1, PGF | KDR 13/4885FLT1 5/4885PDGFRB 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.